Construction and application of spontaneous hyperuricemia model in UOX gene knockout mice
Knocking out the UOX gene in mice through CRISPR/Cas9 technology solves the problem that the existing hyperuricemia model cannot simulate human uric acid metabolism and high embryo mortality for a long time, and builds a scientific, reasonable and efficient hyperuricemia mouse model, meeting the needs of research and drug screening.
Patent Information
- Application Number
- CN202410133694.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-31
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-01-31
AI Technical Summary
The existing animal models of hyperuricemia cannot simulate human uric acid metabolism in a long and stable manner, and the problem of high embryonic lethality through gene knockout method is difficult to meet research needs.
The gRNA targeting UOX gene was designed using CRISPR/Cas9 technology, and the UOX gene was knocked out in C57BL/6 background mice through CRISPR/Cas9 gene editing technology, and the spontaneous hyperuricemia model of UOX knockout mice was constructed to ensure gene function. A scientific, reasonable, efficient and long-term stable mouse model of hyperuricemia was missing and established.
A mouse model with a continuous and stable increase in blood uric acid concentration and multiple hyperuricemia-related phenotypes was successfully constructed. The birth rate of hybrid homozygous fertilization is in line with Mendel's law, no embryo mortality, prolonged survival, and is suitable for research and drug screening.
Smart Images

Figure CN117965638B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of animal models, and particularly relates to a construction method and application of a spontaneous hyperuricemia model of UOX gene knockout mice. Background Art
[0002] With the changes in people's lifestyles and dietary structures, hyperuricemia has become the second largest metabolic disease after diabetes. The overall prevalence in my country and even the world has increased year by year, and is showing a trend of younger age. In addition to gout, elevated blood uric acid levels are also related to the occurrence and development of multi-system diseases such as endocrine metabolism, kidneys, cardiovascular and cerebrovascular diseases, which seriously threaten human health and quality of life. Mammals other than humans all have urate oxidase (UOX), and their blood uric acid levels are extremely low, so it is challenging to establish a stably elevated hyperuricemia animal model. Despite decades of research and development efforts, due to the complexity of the causes and pathogenesis of hyperuricemia, there is still a lack of hyperuricemia experimental animal models that highly simulate human uric acid metabolism worldwide, which cannot meet the research needs of pathogenesis and modern drug development.
[0003] The mouse hyperuricemia models reported so far can be roughly divided into two categories: environmental induction and genetic modification. The principles of replicating models through environmental factors include: (1) increasing the raw materials for uric acid production: adding high-purine, high-fructose foods or uric acid precursors to feed; (2) inhibiting the excretion pathway of uric acid: using adenine, niacin, ethambutol, etc. to inhibit the excretion of uric acid by the kidneys, thereby increasing the blood uric acid concentration and forming hyperuricemia; (3) inhibiting UOX activity: the structure of potassium oxonate is similar to the purine ring of uric acid, and it competitively binds to UOX, partially inhibiting its activity, causing an increase in uric acid in the animal body. The above animal models that are currently widely used all have certain problems and cannot meet the needs of longer-term research. First, due to the difference in uric acid metabolism between animals and humans, the blood uric acid level only increased by 1.5 to 2.1 times, which is difficult to reach a level similar to human hyperuricemia; secondly, when choosing the feeding method for administration, the quality of modeling is affected by individual differences in animals and food intake, and it is difficult to control the differences between groups; in addition, given that the rat kidneys have a strong ability to excrete uric acid, continuous modeling when high uric acid occurs may lead to a decrease in uric acid levels, and it is more difficult to choose a reasonable modeling time period.
[0004] Genetic technology is to generate a long-term stable spontaneous mouse hyperuricemia model by genetically modifying the mouse homologous gene related to human hyperuricemia. Given that the gene encoding UOX is inactivated in humans, genetic modification of the mouse homologous gene UOX is undoubtedly the most important target, which can produce a "human-like" hyperuricemia model. Researchers have used two UOX knockout methods to construct a hyperuricemia mouse model, as shown in Table 1.
[0005] Table 1
[0006]
[0007] For example, in 1993, Wu et al. first constructed UOX - / - In this model, a neomycin selection cassette was inserted into exon 3 of UOX to mediate the disruption of the UOX gene and to move the gene open reading frame. The cassette was inserted into embryonic stem cells of 129 / SvEv mice and injected into C57BL / 6J mouse blastocysts after homologous recombination and embryonic stem cell selection to generate chimeras. UOX - / - Mice were crossed with heterozygous UOX + / - Mice were generated with a hybrid genetic background (C57BL / 6J×129Sv), UOX - / - The average serum urate concentration of mice was 11.0±1.7 mg / dL, which was 12 times that of wild-type mice, but heterozygous UOX - / - The mouse birth rate was 7.1%, much lower than the expected 25%, indicating that UOX - / - Genotype is associated with embryonic lethality. In 2018, Chinese scientists Lu et al. used transcription activator-like effector nuclease (TALEN) technology to delete a 28-base pair region in UOX exon 3 and generated another UOX knockout mouse model in the C57BL / 6J background. - / - Mice had moderately elevated serum uric acid concentrations, similar to human hyperuricemia (8.7±2.3 mg / dL in males and 7.1±1.6 mg / dL in females), and UOX - / - The birth rate of mice was 15.9%, and there was also the problem of embryonic lethality. Mice in this model had renal dysfunction, and male UOX - / - The mice also developed metabolic disorders, decreased insulin secretion, and increased susceptibility to diabetes, while female mice developed hypertension accompanied by lipid metabolism disorders. It can be seen that embryonic lethality is one of the main challenges in developing UOX knockout mouse models.
[0008] In order to produce a mouse model with blood uric acid levels equivalent to human hyperuricemia, it is necessary to knock out the UOX gene. Currently, there are not many hyperuricemia mouse models established through UOX gene intervention, and the embryonic lethality rate is high. As the world's most cutting-edge genome targeted editing technology, CRISPR / Cas9 technology has the advantages of low cost, easy operation, and high efficiency. It is very popular in the construction of human disease models in mammals, genetic engineering, gene therapy and other fields. At present, there are few studies using CRISPR / Cas9 technology to construct UOX - / - Mouse models, etc. Summary of the invention
[0009] In order to overcome the above-mentioned shortcomings of the prior art, the main purpose of the present invention is to provide a method for constructing a spontaneous hyperuricemia model in UOX gene knockout mice, utilize CRISPR / Cas9 technology to efficiently knock out the UOX gene, and establish a scientific, reasonable, efficient and long-term stable hyperuricemia mouse model that highly simulates human uric acid metabolism.
[0010] Another object of the present invention is to provide a spontaneous hyperuricemia model of UOX gene knockout mice for use in the study of the pathogenesis of hyperuricemia-related kidney disease, cardiovascular disease and glucose metabolism disorders, drug development and / or drug screening.
[0011] To achieve the above object, the present invention adopts the following technical solution:
[0012] The present invention provides a method for constructing a UOX gene knockout mouse spontaneous hyperuricemia model, using C57BL / 6 background mice as the subject, comprising the following steps:
[0013] S1. Design target gRNA for knockout of UOX gene (NCBI Gene ID: 22262) by CRISPR / Cas9;
[0014] S2. Design and synthesize gRNA primers, whose sequences are shown in SEQ ID NO: 3 and SEQ ID NO: 4;
[0015] S3, using the pUC57-T7-gRNA plasmid as a template, using the gRNA primers to perform a PCR reaction, detecting the PCR product by electrophoresis, and purifying to obtain a PCR purified product;
[0016] S4, the PCR purified product is transcribed in vitro to obtain gRNA, the sequences of which are shown in SEQ ID NO: 1 and SEQ ID NO: 2;
[0017] S5, the gRNA and Cas9 protein are introduced into C57BL / 6 background mice;
[0018] S6. Subculture the C57BL / 6 background mice described in step S5 to obtain stably inherited UOX gene knockout C57BL / 6 mice.
[0019] Preferably, in step S1, the target gRNA is located in exon 2-4, intron 1-2 and intron 4-5 of the UOX gene sequence of the C57BL / 6 background mouse, and the knockout region is 3.3kb.
[0020] Preferably, in step S4, the gRNA includes gRNA1 and gRNA2, and the sequences are shown in SEQ ID NO:1 and SEQ ID NO:2, respectively:
[0021] gRNA1: GTTAACTCCAAACTATATAG (SEQ ID NO: 1);
[0022] gRNA2: GGTTACTGGATCATTGGTAC (SEQ ID NO: 2).
[0023] Preferably, in step S2, the gRNA primers are SgRNA-universal-PCR-F and SgRNA-universal-PCR-R, and their sequences are shown in SEQ ID NO: 3 and SEQ ID NO: 4, respectively;
[0024] SgRNA-universal-PCR-F: TCTCGCGCGTTTCGGTGATGACGG (SEQ ID NO: 3);
[0025] SgRNA-universal-PCR-R: AAAAAAAGCACCGACTCGGTGCCACTTTTTC (SEQ ID NO: 4).
[0026] Preferably, in step S3, the pUC57-T7-gRNA plasmid includes pUC57-T7-gRNA1 plasmid and pUC57-T7-gRNA2 plasmid, and the sequences are shown in SEQ ID NO:5 and SEQ ID NO:6, respectively;
[0027] pUC57-T7-gRNA1:CCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTCGAGCTCGGTACCTCGCGAATGCATCTAGATATCGGATCCCTAATACGACTCACTATAGACAGGTCATGTGTTACGGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT(SEQ ID NO:5);
[0028] pUC57-T7-gRNA2: (SEQ ID NO:6).
[0029] Preferably, in step S5, the step of introducing the gRNA and Cas9 protein into C57BL / 6 background mice is: the gRNA and Cas9 protein are microinjected into fertilized oocytes of C57BL / 6 background mice, wherein the final concentration of the gRNA is 400 ng / μL, and the final concentration of the Cas9 protein is 500 ng / μL.
[0030] Preferably, in step S6, the subculture method comprises:
[0031] A1. Perform UOX gene knockout detection on C57BL / 6 background mice introduced with the gRNA and Cas9 protein to determine the efficiency of UOX target knockout in F0 generation mice;
[0032] A2 and F0 generations of adult mice with successful UOX gene knockout (UOX - / - ) were crossed with wild-type C57BL / 6 mice to obtain F1 embryos. After genotyping, F1 heterozygous mice (UOX + / - );
[0033] A3, F1 generation heterozygous mice (UOX + / - ) to obtain F2 generation mice;
[0034] A4. The F2 generation mice were identified by genotyping to obtain homozygous UOX gene knockout mice.
[0035] More preferably, in step A1, the primers used for the UOX gene knockout detection are F1 and R1, and the sequences are shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively;
[0036] F1: GGCTCTGCATTGCTGAGAGTATTC (SEQ ID NO: 7);
[0037] R1: AATGGGACACCAGCTTTAGGAG (SEQ ID NO: 8).
[0038] More preferably, in step A2, the primers used for identifying the genotype of the F1 embryo are F2 and R2, and the sequences are shown in SEQ ID NO:9 and SEQ ID NO:10 respectively;
[0039] F2: GCAATGAACATCTGTGAGCACTTC (SEQ ID NO:9);
[0040] R2: ACCTGCCGACTCTTGAAGAATAG (SEQ ID NO: 10).
[0041] Preferably, in step A4, the peak mortality period of homozygous UOX gene knockout mice is from birth to 4 to 5 weeks, and the median survival period of mice that survive 4 to 5 weeks later is 87 days.
[0042] The present invention also provides a UOX gene knockout mouse spontaneous hyperuricemia model for use in the pathogenesis research of hyperuricemia-related kidney, cardiovascular diseases and glucose metabolism disorders, drug development and / or drug screening. The UOX gene knockout mouse spontaneous hyperuricemia model is obtained by any of the methods for constructing the UOX gene knockout mouse spontaneous hyperuricemia model.
[0043] Compared with the prior art, the beneficial effects of the present invention are as follows: the present invention uses CRISPR / Cas9 gene editing technology and non-homologous recombination repair to introduce mutations, so that the gene protein reading frame is shifted to cause UOX functional loss, and the UOX gene is accurately knocked out (exon2-4 of the UOX-201 transcript is the knockout region, about 3.3Kb), and a spontaneous hyperuricemia model of UOX gene knockout mice is successfully constructed. After phenotypic identification and survival rate evaluation, a scientific, reasonable, efficient and long-term stable hyperuricemia mouse model that highly simulates human uric acid metabolism is screened. The advantages of this model include: 1) It has The results showed that the mice had a consistent, sustained and stable increase in blood uric acid concentration; 2) they had multiple hyperuricemia-related phenotypes, including renal impairment and renal tissue pathological changes, hypertension, cardiac contraction reduction and myocardial tissue pathological changes, and glucose metabolism disorders; 3) the birth rate of hybrid homozygous mice was 25%, which was in line with Mendel's law, indicating that there was no embryonic lethality; 4) by maintaining and breeding these mice, uric acid-related physiological as well as genomic and epigenomic changes could be measured in the offspring; (5) the median survival of UOX gene knockout mice that survived to 4-5 weeks was 87 days. After allopurinol intervention, the survival of the mice was further extended to more than 16 weeks. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 Schematic diagram of the method for constructing a spontaneous hyperuricemia model of UOX gene knockout mice in the examples.
[0045] Figure 2 Identification of the spontaneous hyperuricemia model of UOX gene knockout mice in the example; A: DNA gel electrophoresis to identify the genotype of UOX gene knockout mice; B: UOX mRNA level in the liver of UOX gene knockout mice; C: UOX protein level in the liver of UOX gene knockout mice; D: Immunohistochemistry shows the expression of UOX in the liver tissue of UOX gene knockout mice, scale bar is 40μm.
[0046] Figure 3 is the blood uric acid level (μmol / L) of UOX gene knockout mice in the example.
[0047] Figure 4 The cardiovascular damage of UOX gene knockout mice in the example; A: non-invasive arterial systolic pressure; B: echocardiography detection example; C: cardiac contractile function index measured by echocardiography; D: WGE staining of myocardial tissue; E: HE staining of myocardial tissue.
[0048] Figure 5 The following are the pathological changes in kidney tissue of UOX gene knockout mice in the examples; A: glomerulus; B: renal tubule and interstitium; C: renal medulla. DETAILED DESCRIPTION
[0049] In order to make the purpose, technical solution and advantages of the embodiment of the present invention clearer, the technical solution of the embodiment of the present invention will be clearly and completely described in conjunction with the drawings of the embodiment of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all of the embodiments. Based on the described embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention.
[0050] In the following examples, CRISPR / Cas9 technology was used to modify the UOX gene in fertilized oocytes of C57BL / 6 background mice and introduced into surrogate mothers. - / - Mouse hyperuricemia model. Among them, the UOX gene (www.ncbi.nlm.nih.gov / gene / 22262) is located on chromosome 3, with 8 exons and 6 transcripts. According to the structure of the UOX gene, exon2-4 of the transcript of UOX-201 (ENSMUST00000029837.13) was selected as the knockout region. The knockout region is about 3.3kb, which encodes 303 amino acids. After knocking out, the purpose of destroying the gene can be achieved ( Figure 1 ).
[0051] Example 1
[0052] In this example, a spontaneous hyperuricemia model of UOX gene knockout mice was constructed, and the steps were as follows:
[0053] 1.1 Feeding of mice: The experimental animals were wild-type C57BL / 6 female mice (SPF grade, 3-4 weeks old); wild-type male C57BL / 6 mice (SPF grade, 6-8 weeks old), all from Jiangsu Jicuikang Biotechnology Co., Ltd. [SCXK (Su) 02018-0008)]. The experimental animals were kept in an SPF animal breeding room, the temperature of the breeding environment was 20-24 ° C, the relative humidity was 50%-70%, the light rhythm was 12D:12L, the working illumination was 150-300LX, the air flow speed was 0.1-0.2m / s, the noise was ≤60dB, and the feed was SPF ordinary mouse pellet feed (calorie, crude protein, crude fat, crude fiber, crude ash powder, calcium, and phosphorus content were 140.0MJ / kg, 22.3%, 4.49%, 3.93%, 5.24%, 1.08%, and 0.68%, respectively).
[0054] 1.2 Model construction: The preparation of the mouse model and the breeding of the F1 generation were entrusted to Jiangsu Jicuikang Biotechnology Co., Ltd. [SCXK(Su)02018-0008)], and the specific process is as follows:
[0055] 1.2.1 Obtaining sgRNA
[0056] A. sgRNA Primer Design
[0057] (1) The gene sequence of mouse UOX was searched and downloaded from the Ensembl database. Based on the structure of the UOX gene, the approximately 3.3 kb region on exon2-4 of the UOX-201 (ENSMUST00000029837.13) transcript was selected as the target, as shown in Table 2.
[0058] Table 2
[0059]
[0060] Two sgRNAs were designed respectively, and the upstream PCR primer SgRNA-universal-PCR-F and the downstream primer SgRNA-universal-PCR-R were designed according to the sgRNA structure. The specific primer sequences are as follows:
[0061] SgRNA-universal-PCR-F:
[0062] TCTCGCGCGTTTCGGTGATGACGG (SEQ ID NO: 3).
[0063] SgRNA-universal-PCR-R:
[0064] AAAAAAAGCACCGACTCGGTGCCACTTTTTC (SEQ ID NO: 4).
[0065] B. Preparation of transcription template
[0066] The upstream primer SgRNA-universal-PCR-F and the downstream primer SgRNA-universal-PCR-R were mixed, and the amplification reagent was added to the pUC57-T7-gRNA1 and pUC57-T7-gRNA2 vectors (purchased from Addgene) and then the sgRNA template was amplified twice by PCR. The reaction conditions were 98°C pre-denaturation for 5 min; 35 cycles were performed according to the cycle program (98°C 30s, 60°C 30s, 72°C 30s); 72°C extension for 5 min. The reaction product was subjected to 2% agarose gel electrophoresis, and the DNA in the agarose gel was recovered and purified. The mixed buffer, ATP, TTP, CTP, GTP, sgRNA template, T7 enzyme, and nuclease-free water were incubated at 37°C for 2h, in vitro transcription was performed, DNase 1μL was added, and incubated at 37°C for 15-20min; the sgRNA was purified, and the size of the two sgRNA sequence fragments was confirmed to be consistent with the designed bp size.
[0067] gRNA1 sequence: GTTAACTCCAAACTATATAG (SEQ ID NO: 1)
[0068] gRNA2 sequence: GGTTACTGGATCATTGGTAC (SEQ ID NO: 2).
[0069] 1.2.2 Microinjection
[0070] UOX-sgRNA and CAS protein were mixed and injected into the fertilized eggs of C57BL / 6 mice by fertilized egg microinjection, and then transplanted into the oviduct of pseudopregnant mice to complete embryonic development.
[0071] 1.2.3 Birth and identification of F0 generation mice
[0072] The tails of mice were cut 3 weeks after birth for genome extraction, and PCR was used to verify the gene knockout. The detection primers are as follows:
[0073] ①KO sequence:
[0074] F1: GGCTCTGCATTGCTGAGAGTATTC (SEQ ID NO: 7);
[0075] R1: AATGGGACACCAGCTTTAGGAG (SEQ ID NO: 8).
[0076] ②WT sequence:
[0077] F2: GCAATGAACATCTGTGAGCACTTC (SEQ ID NO: 9);
[0078] R2: ACCTGCCGACTCTTGAAGAATAG (SEQ ID NO: 10).
[0079] The PCR reaction conditions were as follows: 95°C pre-denaturation for 5 min; 35 cycles according to the cycle program (95°C for 30 s, 65°C for 30 s, 72°C for 60 s); and 68°C extension for 5 min. DNA gel electrophoresis was performed at a constant voltage of 120 V for 30 min, and the band size was observed by taking photos under long-wave ultraviolet light. UOX knockout mice (UOX-KO, UOX - / - ) showed a band of approximately 462 bp, and the wild-type mouse (WT) band was approximately 313 bp ( Figure 2 A).
[0080] 1.2.4F2 generation UOX - / - Homozygous strain construction
[0081] A. F1 generation mice breeding: F0 generation mice were crossed with wild C57BL / 6 mice to obtain F1 generation heterozygous mice (UOX + / - ), PCR confirmed partial knockout of UOX gene, DNA gel electrophoresis showed two bands of 462 bp and 313 bp ( Figure 2 A).
[0082] B. F1 heterozygous mice (UOX + / - ) were self-fertilized to obtain a stable homozygous mouse strain (UOX - / - ), UOX born from heterozygous mating - / - The mouse birth rate is approximately 25% with no embryonic lethality.
[0083] 1.3 Survival rate observation
[0084] Homozygous UOX - / - The peak mortality period for mice is from birth to 4 to 5 weeks (mortality rate is about 75.5%), and the median survival period of mice that are still alive after 4 to 5 weeks is 87 days.
[0085] Example 2
[0086] This example verifies Example 1 to construct a UOX gene knockout mouse model for spontaneous hyperuricemia, and to identify the genotype and determine the mRNA level and protein level. The method is as follows:
[0087] 2.1 Extract DNA from mouse tissues and perform PCR to identify the mouse genotype (same as 1.2.3 in Example 1).
[0088] 2.2 After the mice were separated into cages, they were euthanized and their liver tissues were removed. Total mRNA and protein were extracted respectively, and Real-time qPCR was used to detect the expression of UOX gene at the mRNA level.
[0089] like Figure 2 As shown, compared with wild-type (WT) mice, UOX - / - UOX mRNA is not detectable in mice, but UOX + / - The transcription level of UOX gene in mice decreased by about 25% ( Figure 2 B). Western blot was used to detect the expression of UOX gene at the mRNA level. The results showed that UOX - / - Mice do not express UOX protein, but UOX + / - The protein expression level of mice was lower than that of wild-type (WT) mice ( Figure 2 C) The results of UOX immunohistochemistry in liver tissue showed that UOX - / - UOX is hardly expressed in mouse liver. Figure 2D), proves that UOX gene knockout was successful, ****P<0.0001, vs WT, n=6.
[0090] Example 3
[0091] This example evaluates the biochemical phenotypes such as blood uric acid in the spontaneous hyperuricemia model of the UOX gene knockout mice constructed in Example 1, and the method is as follows:
[0092] Eight-week-old mice were fasted for 12 hours, and blood was collected from the retro-orbital vein at 8 a.m. The serum was centrifuged at 4°C and 3000 r / min for 15 min to obtain serum. The biochemical indicators such as blood uric acid, urea nitrogen, creatinine, blood glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were measured using an automatic biochemical analyzer. - / - The blood uric acid of mice was 1210.22±150.58μmol / L, much higher than UOX + / - and (153.43±4.93μmol / L)WT mice (151.53±13.98μmol / L) (P<0.001) ( Figure 3 ). In addition, UOX - / - The urea nitrogen and serum creatinine of mice were higher than those of the other two groups, indicating renal damage. - / - The fasting blood glucose of mice increased significantly, while there was no significant difference in the changes of blood lipids (P>0.05) (Table 3).
[0093] Table 3: Biochemical parameters of UOX knockout mice (X±SD)
[0094]
[0095]
[0096] Compared with the other two groups, *: P<0.001; **: P<0.0001.
[0097] Example 4
[0098] This example evaluates the renal pathological changes in the spontaneous hyperuricemia model of 8-week-old UOX knockout mice constructed in Example 1. HE staining results showed that some glomeruli of hyperuricemia mice were significantly enlarged with severe bleeding, glomerular capsule stenosis, mesangial expansion, and increased eosinophilic matrix in the mesangium ( Figure 4 A), there is a large number of mononuclear cell infiltration and severe bleeding in the renal interstitium, degeneration and necrosis of renal tubular epithelial cells, nuclear condensation, and a large amount of eosinophilic red homogeneous amyloid exudation and granular casts in the renal tubules. The renal tubular wall is thinned and the renal tubules are dilated to form cysts ( Figure 4 B), massive bleeding in the renal medulla ( Figure 4C). The above results suggest that the UOX - / - Hyperuricemia mice showed kidney tissue damage.
[0099] Example 5
[0100] This example evaluates the blood pressure and cardiac involvement of the spontaneous hyperuricemia model of UOX gene knockout mice constructed in Example 1, and the method is as follows:
[0101] Take 8-week-old UOX from the same litter - / - Mouse, UOX + / - The tail artery non-invasive arterial pressure was measured in mice and WT mice. - / - The average systolic blood pressure of mice was 155.25±9.48 mmHg, which was significantly higher than that of wild mice (109.53±11.02 mmHg), P<0.0001( Figure 5 A).
[0102] The ultra-high-frequency and high-resolution small animal ultrasound imaging system (Vevo2100) was used to perform cardiac ultrasound examination of mice. The results showed that compared with WT mice, UOX - / - The mice showed signs of heart failure, including decreased left ventricular ejection fraction, fractional shortening, stroke volume, and cardiac output ( Figure 5 B, 5C). In terms of tissue morphology, wheat germ agglutinin (WGA) staining and HE staining were used to observe the morphology of cardiomyocytes and cardiac structure. The results showed that UOX - / - The mouse myocardial cells were hypertrophic, the muscle bundles were widened, the heart wall was thickened, the heart cavity volume was significantly reduced, some myocardial fibers were broken, and some myocardial cytoplasm was vacuolated ( Figure 5 D, 5E). The above results all indicate that hyperuricemia mice have pathological changes in cardiac structure and decreased cardiac contractile function.
[0103] In summary, the present invention uses CRISPR / Cas9 gene editing technology and non-homologous recombination repair to introduce mutations, causing the gene protein reading frame to shift and cause UOX functional loss, accurately knocking out the UOX gene (exon2-4 of the UOX-201 transcript is the knockout region, about 3.3Kb), and establishing and screening a scientific, reasonable, efficient and long-term stable hyperuricemia mouse model that highly simulates human uric acid metabolism, providing the necessary tools for conducting various studies on hyperuricemia-related metabolic diseases, cardiovascular diseases, kidney diseases, etc., as well as drug development and drug screening.
[0104] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. Application of a spontaneous hyperuricemia model of UOX gene knockout mice in drug screening for hyperuricemia-related kidney and cardiovascular diseases and glucose metabolism disorders. It is characterized in that The method for constructing the UOX gene knockout mouse spontaneous hyperuricemia model comprises the following steps: S1. Design a target gRNA for UOX gene knockout by CRISPR / Cas9. The target gRNA is located in exon 2-4 of the UOX gene sequence of C57BL / 6 background mice. The target is designed and targeted at intron 1-2 and intron 4-5, and the knockout region is 3.3kb. S2. Design and synthesize gRNA primers, namely SgRNA-universal-PCR-F and SgRNA-universal-PCR-R, with sequences shown in SEQ ID NO: 3 and SEQ ID NO: 4, respectively; S3. Using the pUC57-T7-gRNA plasmid as a template, using the gRNA primers to perform a PCR reaction, detecting the PCR product by electrophoresis, and purifying to obtain a PCR purified product; the pUC57-T7-gRNA plasmid includes a pUC57-T7-gRNA1 plasmid and a pUC57-T7-gRNA2 plasmid, and the sequences are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively; S4. The PCR purified product is transcribed in vitro to obtain gRNA, which includes gRNA1 and gRNA2, whose sequences are shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively; S5, the gRNA and Cas9 protein were microinjected into fertilized oocytes of C57BL / 6 background mice, wherein the final concentration of gRNA was 400 ng / μL, and the final concentration of Cas9 protein was 500 ng / μL; S6. Subculturing the C57BL / 6 background mice to obtain stable inherited UOX gene knockout C57BL / 6 mice; the subculturing method comprises: A1. Perform UOX gene knockout test on C57BL / 6 background mice introduced with the gRNA and Cas9 protein to determine the F0 generation mice UOX The efficiency of target knockout; A2 and F0 generations of adult mice with successful UOX gene knockout - / - Crossbreeding with wild-type C57BL / 6 mice to obtain F1 embryos, and genotyping to obtain F1 heterozygous mice UOX + / - ; A3, F1 generation heterozygous mice UOX + / - Inbreeding to obtain F2 generation mice; A4, the F2 generation mice are genotyped and homozygous for UOX gene knockout are obtained; In step A4, the peak period of death for homozygous UOX gene knockout mice is from birth to 4 to 5 weeks, and the median survival period of mice that survive 4 to 5 weeks later is 87 days; The primers used for the UOX gene knockout detection are F1 and R1, and their sequences are shown in SEQ ID NO:7 and SEQ ID NO:8 respectively; the primers used for the F1 embryo genotype identification are F2 and R2, and their sequences are shown in SEQ ID NO:9 and SEQ ID NO:10 respectively.
Citation Information
Patent Citations
Method for parameterizing pin-by-pin calculation few group constant of pressurized water reactor
CN107122564A
UOX gene knockout mouse model and construction method thereof
CN112342249A
Use of PLAG or PLAG-inhibitors to diagnose and / or treat disease
WO2004023869A1
Multilayer genetic safety kill circuits based on single CAS9 protein and multiple engineered grna in mammalian cells
WO2017040786A1
